Unadjusted | Adjusted Model 1a | Adjusted Model 2a | ||||
---|---|---|---|---|---|---|
Characteristic | Risk Ratio (95% CI) | P value | Risk Ratio (95% CI) | P value | Risk Ratio (95% CI) | P value |
Age, years | ||||||
≤ 30 | Ref. | Ref. | Ref. | |||
30–34 | 1.02 (0.72–1.45) | 0.908 | 1.04 (0.64–1.68) | 0.872 | 1.00 (0.60–1.66) | 0.997 |
35–39 | 0.66 (0.42–1.03) | 0.068 | 0.72 (0.41–1.25) | 0.242 | 0.62 (0.34–1.13) | 0.119 |
≥ 40 | 0.81 (0.55–1.19) | 0.285 | 0.85 (0.51–1.39) | 0.511 | 0.83 (0.49–1.41) | 0.489 |
Gender | ||||||
Women | Ref. | Ref. | Ref. | |||
Men | 1.10 (0.82–1.49) | 0.520 | 1.10 (0.75–1.62) | 0.623 | 1.04 (0.69–1.57) | 0.838 |
Chemotherapy indications | ||||||
1 chemotherapy indication | Ref. | Ref. | Ref. | |||
2 chemotherapy indications | 1.75 (1.26–2.44) | 0.001 | 1.82 (1.19–2.79) | 0.006 | 1.86 (1.20–2.87) | 0.005 |
≥ 3 chemotherapy indications | 2.18 (1.58–3.01) | < 0.001 | 2.30 (1.46–3.60) | < 0.001 | 2.43 (1.51–3.91) | < 0.001 |
CD4+ T cells, count/μl | ||||||
> 350 | Ref. | Ref. | Ref. | |||
201–350 | 1.55 (0.93–2.59) | 0.091 | 1.61 (0.85–3.06) | 0.143 | 1.54 (0.80–2.98) | 0.200 |
51–200 | 1.65 (1.03–2.63) | 0.036 | 1.74 (0.97–3.11) | 0.063 | 1.86 (1.03–3.37) | 0.040 |
< 50 | 1.11 (0.60–2.07) | 0.731 | 1.04 (0.49–2.20) | 0.913 | 1.04 (0.49–2.23) | 0.909 |
CD4 unknown | 1.06 (0.65–1.74) | 0.720 | 1.07 (0.60–1.92) | 0.820 | 1.03 (0.56–1.89) | 0.921 |
Education | ||||||
None | Ref. | Ref. | ||||
Primary | 1.00 (0.55–1.80) | 0.990 | 0.85 (0.39–1.85) | 0.689 | ||
Secondary | 1.18 (0.64–2.19) | 0.590 | 1.09 (0.48–2.44) | 0.842 | ||
Tertiary | 1.31 (0.56–3.07) | 0.540 | 1.20 (0.38–3.82) | 0.760 | ||
Travel time to clinic | ||||||
< 30 min | Ref. | Ref. | ||||
30–59 min | 1.05 (0.67–1.65) | 0.837 | 1.06 (0.60–1.87) | 0.835 | ||
1–2 h | 1.22 (0.78–1.91) | 0.387 | 1.18 0.67–2.07) | 0.567 | ||
> 2 h | 1.42 (0.91–2.20) | 0.119 | 1.37 (0.76–2.45) | 0.295 | ||
Water piped into home | ||||||
No | Ref. | Ref. | ||||
Yes | 1.11 (0.74–1.68) | 0.604 | 1.14 (0.65–1.97) | 0.652 |